## P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/26/2019 AVERAGE SEVERITY GRADES[b]

Resveratrol CAS Number: 501-36-0

Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06

Lab: BAT

Species/Strain: MICE/B6C3F1

Test Type: 14-DAY

Route: GAVAGE

NTP Study Number: C20323

**Lock Date:** 12/15/2006

Cage Range: ALL

Date Range: ALL

**Reasons For Removal:** ALL

Removal Date Range: ALL

Treatment Groups: Include ALL

Study Gender: Both

**TDMSE Version:** 3.0.2.3\_002

PWG Approval Date: NONE

Species/Strain: MICE/B6C3F1

Test Type: 14-DAY

Route: GAVAGE

## P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/26/2019 AVERAGE SEVERITY GRADES[b]

Resveratrol

**CAS Number:** 501-36-0

Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06

Lab: BAT

B6C3F1 MICE MALE	0 mg/kg	156 mg/kg	312 mg/kg	625 mg/kg	1250 mg/kg	2500 mg/kg
Disposition Summary						
Animals Initially In Study Early Deaths Survivors	5	5	5	5	5	5
Terminal Sacrifice Animals Examined Microscopically	5 5	5	5	5	5	5 5
ALIMENTARY SYSTEM						
Liver Inflammation	(5)	(0)	(0)	(0)	(0)	(5) 1 [1.0]
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM						
None						
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
None						
HEMATOPOIETIC SYSTEM						
Thymus	(5)	(0)	(0)	(0)	(0)	(5)

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Test Type: 14-DAY

Route: GAVAGE

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH **AVERAGE SEVERITY GRADES[b]** 

**CAS Number:** 501-36-0

Resveratrol

Date Report Requested: 08/26/2019

Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06

2500 mg/kg

Lab: BAT

Species/Strain: MICE/B6C3F1 **B6C3F1 MICE MALE** 0 mg/kg 156 mg/kg 312 mg/kg 625 mg/kg 1250 mg/kg

INTEGUMENTARY SYSTEM

None

MUSCULOSKELETAL SYSTEM

None

**NERVOUS SYSTEM** 

None

RESPIRATORY SYSTEM

None

SPECIAL SENSES SYSTEM

None

**URINARY SYSTEM** 

None

\*\*\* END OF MALE \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

## P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/26/2019 AVERAGE SEVERITY GRADES[b]

Resveratrol CAS Number: 501-36-0

Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06

Lab: BAT

Route: GAVAGE Species/Strain: MICE/B6C3F1

Test Type: 14-DAY

B6C3F1 MICE FEMALE	0 mg/kg	156 mg/kg	312 mg/kg	625 mg/kg	1250 mg/kg	2500 mg/kg
Disposition Summary						
Animals Initially In Study Early Deaths Survivors	5	5	5	5	5	5
Terminal Sacrifice Animals Examined Microscopically	5 5	5	5	5	5	5 5
ALIMENTARY SYSTEM						
Liver	(5)	(0)	(0)	(0)	(0)	(5)
CARDIOVASCULAR SYSTEM						
None						
ENDOCRINE SYSTEM	,					
None						
GENERAL BODY SYSTEM						
None						
GENITAL SYSTEM						
Ovary Hemorrhage	(1) 1 [4.0]	(0)	(0)	(0)	(0)	(0)
HEMATOPOIETIC SYSTEM						
Thymus	(5)	(0)	(0)	(0)	(0)	(5)

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)

Species/Strain: MICE/B6C3F1

Test Type: 14-DAY

Route: GAVAGE

P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH Date Report Requested: 08/26/2019 AVERAGE SEVERITY GRADES[b]

Resveratrol **CAS Number:** 501-36-0

Time Report Requested: 17:01:32 First Dose M/F: 10/16/06 / 10/16/06

Lab: BAT

B6C3F1 MICE FEMALE	0 mg/kg	156 mg/kg	312 mg/kg	625 mg/kg	1250 mg/kg	2500 mg/kg
INTEGUMENTARY SYSTEM						
None						
MUSCULOSKELETAL SYSTEM						
None						
NERVOUS SYSTEM						
None						
RESPIRATORY SYSTEM						
None						
SPECIAL SENSES SYSTEM						
None						
URINARY SYSTEM						
None						

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion b-Average severity grade(1-minimal;2-mild;3-moderate;4-marked)